Glucagon-like peptide-1 (7-36)-NH2: a physiological inhibitor of gastric acid secretion in man. 1990

D J O'Halloran, and G C Nikou, and B Kreymann, and M A Ghatei, and S R Bloom
Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London.

Glucagon-like peptide (GLP)-1 (7-36)-NH2 is a peptide found in the mucosal endocrine cells of the intestine, and plasma levels of GLP-1 (7-36)-NH2 immunoreactivity show a rise after the ingestion of a fat or mixed-component meal. We investigated the effects of physiological infusion of GLP-1 (7-36)-NH2 on a submaximal gastric acid secretion in healthy volunteers at a rate known to mimic the observed postprandial rise in plasma concentrations. Corrected gastric acid output decreased to less than 50% and volume output to 33% of stimulated values. After the infusion, the secretion of gastric acid recovered immediately to preinhibition values. These results suggest a novel role for GLP-1 (7-36)-NH2 as a physiological inhibitor of gastric acid secretion in man.

UI MeSH Term Description Entries
D008297 Male Males
D010418 Pentagastrin A synthetic pentapeptide that has effects like gastrin when given parenterally. It stimulates the secretion of gastric acid, pepsin, and intrinsic factor, and has been used as a diagnostic aid. Acignost,Gastrin Pentapeptide,Peptavlon,Pentapeptide, Gastrin
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D003864 Depression, Chemical The decrease in a measurable parameter of a PHYSIOLOGICAL PROCESS, including cellular, microbial, and plant; immunological, cardiovascular, respiratory, reproductive, urinary, digestive, neural, musculoskeletal, ocular, and skin physiological processes; or METABOLIC PROCESS, including enzymatic and other pharmacological processes, by a drug or other chemical. Chemical Depression,Chemical Depressions,Depressions, Chemical
D004763 Glucagon-Like Peptides Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms. Enteroglucagon,Enteroglucagons,Glucagon-Like Peptide,Glucagon-Like Polypeptide,Gut Glucagon,Glucagon-Like Polypeptides,Glucagon Like Peptide,Glucagon Like Peptides,Glucagon Like Polypeptide,Glucagon Like Polypeptides,Glucagon, Gut,Peptide, Glucagon-Like,Polypeptide, Glucagon-Like
D005260 Female Females
D005744 Gastric Acid Hydrochloric acid present in GASTRIC JUICE. Hydrochloric Acid, Gastric,Acids, Gastric,Acids, Gastric Hydrochloric,Gastric Acids,Gastric Hydrochloric Acid,Gastric Hydrochloric Acids,Hydrochloric Acids, Gastric
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

D J O'Halloran, and G C Nikou, and B Kreymann, and M A Ghatei, and S R Bloom
December 1987, Lancet (London, England),
D J O'Halloran, and G C Nikou, and B Kreymann, and M A Ghatei, and S R Bloom
June 1997, Scandinavian journal of gastroenterology,
D J O'Halloran, and G C Nikou, and B Kreymann, and M A Ghatei, and S R Bloom
March 1997, Inflammation research : official journal of the European Histamine Research Society ... [et al.],
D J O'Halloran, and G C Nikou, and B Kreymann, and M A Ghatei, and S R Bloom
March 1997, Inflammation research : official journal of the European Histamine Research Society ... [et al.],
D J O'Halloran, and G C Nikou, and B Kreymann, and M A Ghatei, and S R Bloom
December 1995, The American journal of physiology,
D J O'Halloran, and G C Nikou, and B Kreymann, and M A Ghatei, and S R Bloom
June 1994, Scandinavian journal of gastroenterology,
D J O'Halloran, and G C Nikou, and B Kreymann, and M A Ghatei, and S R Bloom
January 1998, Endocrinology,
D J O'Halloran, and G C Nikou, and B Kreymann, and M A Ghatei, and S R Bloom
February 2009, The Journal of endocrinology,
D J O'Halloran, and G C Nikou, and B Kreymann, and M A Ghatei, and S R Bloom
March 2001, American journal of respiratory and critical care medicine,
D J O'Halloran, and G C Nikou, and B Kreymann, and M A Ghatei, and S R Bloom
October 1998, Molecular neurobiology,
Copied contents to your clipboard!